Contact SCGE
Your email
Message
Send
SCGE Consortium Home
|
About SCGE TCDC
|
Contact Us
|
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis
NCTID
NCT06289452
(View at clinicaltrials.gov)
Description
The goal of this clinical trial is to evaluate the safety and efficacy of IVB102 injection in subjects with XLRS.
(Show More)
Indication
Retinoschisis, Retinal Disease, Retinal Degeneration, Eye Diseases
Compound Name
IVB102
Sponsor
InnoVec Biotherapeutics Inc.
Funder Type
Industry
Status
Recruiting
Enrollment Count
18
Therapy Information
Target Gene/Variant
RS1
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Functional gene replacement
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV
Editor Type
none
Dose 1
Undisclosed low dose
Dose 2
Undisclosed medium dose
Dose 3
Undisclosed high dose
Dose 4
Dose 5
Study Record Dates
Current Stage
Early phase1
Submit Date
2024-02-25
Completion Date
2029-12-31
Last Update
2024-05-07
Participation Criteria
Eligible Age
>=8 Years
Standard Ages
Child, Adult, Older adult
Eligible Sex
MALE
Locations
No.of Trial Sites
1
Locations
China
Regulatory Information
Has US IND
False
Recent Updates
Resources/Links